ANGION BIOMEDICA CORP.

(ANGN)
  Report
Delayed Nasdaq  -  04:00 2022-08-05 pm EDT
1.090 USD   +0.93%
07/25Angion Announces Process to Explore Strategic Alternatives for Enhancing and Preserving Shareholder Value
CI
07/25ANGION BIOMEDICA CORP. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers (form 8-K)
AQ
07/25Angion Biomedica Corp. Announces Resignation of John F. Neylan as Chief Medical Officer and Head of Research, Effective on August 15, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sector Update: Health Care Stocks Little Changed on Thursday

06/30/2022 | 02:00pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ANGION BIOMEDICA CORP. 0.93% 1.09 Delayed Quote.-62.41%
BIONTECH SE 1.48% 183.11 Delayed Quote.-28.97%
CYTOKINETICS, INCORPORATED 10.92% 51.82 Delayed Quote.13.69%
NASDAQ COMPOSITE -0.50% 12657.55 Real-time Quote.-19.10%
PFIZER, INC. -1.18% 49.27 Delayed Quote.-16.56%
UNIVERSAL HEALTH SERVICES, INC. 0.59% 110.35 Delayed Quote.-14.89%
All news about ANGION BIOMEDICA CORP.
07/25Angion Announces Process to Explore Strategic Alternatives for Enhancing and Preserving..
CI
07/25ANGION BIOMEDICA CORP. : Costs Associated with Exit or Disposal Activities, Change in Dire..
AQ
07/25Angion Biomedica Corp. Announces Resignation of John F. Neylan as Chief Medical Officer..
CI
07/25Angion Biomedica to Explore Strategic Alternatives to Boost Shareholder Value
MT
07/25Angion Announces Process to Explore Strategic Alternatives for Enhancing and Preserving..
GL
07/25Angion Announces Process to Explore Strategic Alternatives for Enhancing and Preserving..
AQ
07/18HC Wainwright Downgrades Angion Biomedica to Neutral From Buy
MT
06/30SECTOR UPDATE : Health Care Stocks Swoon Late, Closing Lower
MT
06/30Top Midday Decliners
MT
06/30SECTOR UPDATE : Health Care Stocks Little Changed on Thursday
MT
More news
Analyst Recommendations on ANGION BIOMEDICA CORP.
More recommendations
Financials (USD)
Sales 2022 3,72 M - -
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 32,7 M 32,7 M -
Capi. / Sales 2022 8,77x
Capi. / Sales 2023 20,4x
Nbr of Employees 71
Free-Float 66,0%
Chart ANGION BIOMEDICA CORP.
Duration : Period :
Angion Biomedica Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 1,09
Average target price
Spread / Average Target -
Managers and Directors
Jay R. Venkatesan Chairman, President & Chief Executive Officer
Greg S. Curhan Chief Financial Officer
John F. Neylan Chief Medical Officer, EVP & Head-Research
Jennifer J. Rhodes Secretary, Chief Compliance & Business Officer
Allen R. Nissenson Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ANGION BIOMEDICA CORP.-62.41%33
MODERNA, INC.-26.44%73 092
IQVIA HOLDINGS INC.-16.94%43 781
LONZA GROUP AG-26.44%43 083
SEAGEN INC.13.72%32 426
ALNYLAM PHARMACEUTICALS, INC.28.89%26 235